EP Patent
EP0357369A2 — The use of asymetric membranes in delivery devices
Assigned to Pfizer Inc · Expires 1990-03-07 · 36y expired
What this patent protects
A device for controlled release of an active substance through one or more asymmetric membranes by diffusion and/or osmotic pumping.
USPTO Abstract
A device for controlled release of an active substance through one or more asymmetric membranes by diffusion and/or osmotic pumping.
Drugs covered by this patent
- Xeljanz (Tofacitinib Citrate) · Pfizer
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.